DOI:10.1586/14779072.5.1.9 - Corpus ID: 11255636
Dofetilide: a new class III antiarrhythmic agent
@article{Roukoz2007DofetilideAN, title={Dofetilide: a new class III antiarrhythmic agent}, author={Henri Roukoz and Walid I. Saliba}, journal={Expert Review of Cardiovascular Therapy}, year={2007}, volume={5}, pages={19 - 9}, url={https://api.semanticscholar.org/CorpusID:11255636}}- H. RoukozW. Saliba
- Published inExpert Review of…1 January 2007
- Medicine
Oral dofetilide did not increase mortality in patients with a recent myocardial infarction or congestive heart failure, hence its importance as an alternative medication for the pharmacological conversion of atrial fibrillation and flutter, and maintenance of sinus rhythm after conversion in patients at high risk of sudden death.
70 Citations
Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
- A. P. RieraA. UchidaP. Moffa
- 2008
Medicine
The main new generation class III drugs are: dofetilide, dronedarone, azimilide, and ibutilide, which are the gold standard in the prevention of recurrence of atrial fibrillation and flutter.
Newer Antiarrhythmic Agents for Atrial Fibrillation: Shall we Eventually do away with Proarrhythmia?
- A. Sideris
- 2008
Medicine
Future antiarrhythmic agents will probably be atrial-selective blocking agents without affecting repolarization in the ventricular myocardium and thus avoid ventricular proarrhythmics with its attendant life-threatening consequences.
Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.
- Abhishek JaiswalS. Goldbarg
- 2014
Medicine
Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses
- Helena CarstensenLine KjærT. Jespersen
- 2018
Medicine
The combination of dofetilide and ranolazine showed increased antiarrhythmic effects on acutely induced AF in horses, affecting time to cardioversion, AF vulnerability, and AF duration.
Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
- J. BanchsGiselle A. BaqueroMario D Gonzalez
- 2014
Medicine
D should be considered a pharmacologic alternative when adult patients with CHD develop AT but needs close monitoring for potential ventricular pro-arrhythmia.
Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option
- M. KraftAntonius BüscherC. Schmidt
- 2021
Medicine
The DOxapram Conversion TO Sinus rhythm (DOCTOS)-Trial will reveal whether doxaprams, a potent TASK-1 inhibitor, can be used for acute cardioversion of persistent and paroxysmal AF in patients, potentially leading to a new treatment option for AF.
Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter
- J. BanchsD. WolbretteG. Naccarelli
- 2008
Medicine
Dofetilide is more effective in patients with persistent than in those with paroxysmal AF/AFL, and short-term response does not necessarily predict long-term efficacy.
Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin
This study demonstrates synergistic antiarrhythmic benefits of combined block of IKur and INa, as well as those of INa and combined multi K+-current block of acacetin, without significant alterations of ventricular repolarization and QT intervals.
Dofetilide-Induced Microvolt T-Wave Alternans
- Ilaria MarcantoniRosita LarattaL. Burattini
- 2019
Medicine
In healthy subjects, dofetilide increases occurrence and levels (6 times baseline value on average) of TWA in the hours following its administration, and inhealthy subjects, this phenomenon is associated to malignant ventricular arrhythmias.
...
62 References
Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
- R. FalkA. PollakSteven N. SinghT. Friedrich
- 1997
Medicine
Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group.
- Yaves BashirP. ThomsenA. Camm
- 1995
Medicine
Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris.
- M. L. SedgwickH. RasmussenS. Cobbe
- 1992
Medicine
Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias.
- Y. KobayashiH. AtarashiH. Hayakawa
- 1997
Medicine
The results imply that the suppression of the development and maintenance of reentrant arrhythmias may result from the lengthening effect of dofetilide on the refractoriness and the consequent elimination of the excitable gap at the critical part of theReentrant loop.
Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial
- B. NørgaardK. WachtellE. Simonsen
- 1999
Medicine
Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
- B. NørgaardK. WachtellE. Simonsen
- 1999
Medicine
Intravenous dofetilide is effective in acute termination of AF and AFL of medium duration, with a particularly high efficacy rate in AFL, and a small but serious risk of proarrhythmia must be anticipated.
Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure.
- M. RousseauP. MassartH. Pouleur
- 2001
Medicine
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
- C. Torp-PedersenM. MøllerA. Camm
- 1999
Medicine
In patients with congestive heart failure and reduced left ventricular function, dofetilide was effective in converting atrial fibrillation, preventing its recurrence, and reducing the risk of hospitalization for worsening heart failure.
Atrial fibrillation and atrial flutter.
- Geraets DrKienzle Mg
- 1993
Medicine
The epidemiology, pathophysiology, diagnosis, evaluation, and treatment of atrial fibrillation (AF) and atrial flutter (AFl) are reviewed, and recent developments and controversies in the approach to…
...
Related Papers
Showing 1 through 3 of 0 Related Papers